SRI-31255 is an orally active LRRK2 inhibitor, with IC50 values of 520 nM for human wild-type (WT) and 427 nM for the G2019S mutant. It inhibits kinase activity by binding to the ATP-binding pocket of LRRK2, providing neuroprotective effects. SRI-31255 serves as a lead compound for developing LRRK2-targeted therapies for Parkinsons disease research.
Molecular Weight:
250.3
CAS Number:
[905580-86-1]
Formula:
C15H14N4
Target:
LRRK2
T207344
* VAT and and shipping costs not included. Errors and price changes excepted
